Myasthenia gravis (MG) is a rare autoimmune disease that can impact vision, speech, mobility, and breathing, but treatments are advancing quickly. From surgery and immunosuppressants to new targeted ...

Get the Well Enough newsletter with Harry Bullmore for tips on living a healthier, happier and longer life Get the Well Enough email with Harry Bullmore Former tennis star Monica Seles recently ...

TITUSVILLE, N.J., Feb. 28, 2022 /PRNewswire/ -- In honor of Rare Disease Day on February 28 and the 25-30 million Americans living with rare diseases, 1 the Janssen Pharmaceutical Companies of Johnson ...

For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia gravis in the Phase 2/3 study First FcRn blocker to demonstrate sustained ...

"Publication of the Phase 3 Vivacity-MG3 data in The Lancet Neurology underscores the potential nipocalimab has in providing clinical benefit to people living with generalised myasthenia gravis (gMG), ...

Myasthenia gravis (MG) is a rare autoimmune neuromuscular disorder that causes fluctuating muscle weakness, often affecting daily activities like speaking, walking, or even breathing. While symptoms ...

Myasthenia gravis is a chronic autoimmune disorder that disrupts nerve-to-muscle signaling, causing weakness. Modern treatments help many people live typical life spans and enter remission.

New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the ...

First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin ...

“Findings from the Vibrance-MG study underscore the potential of this investigational therapy for young individuals aged 12 – 17 living with gMG. Results show a significant reduction in IgG of ...

The MarketWatch News Department was not involved in the creation of this content. New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug ...